A cheap, widely sold supplement just did something in a randomized trial that most supplements never manage: it measurably slowed the buildup of calcium in the coronary arteries of people who already have heart disease. The catch, and there is one, is that nobody yet knows whether it prevents a single heart attack.
The supplement is vitamin K2 as menaquinone-7 (MK-7). The trial is VitaK-CAC, published in JAMA Cardiology in 2026.
The Headline Numbers
Participants had symptomatic coronary artery disease (CAD) and a baseline coronary artery calcium (CAC) score between 50 and 400 Agatston units (AU). They took either 360 µg of MK-7 daily or an identical placebo for two years. Median CAC scores in each group moved like this:
| Group | Baseline | Year 1 | Year 2 |
|---|---|---|---|
| Placebo | 145 AU | 173 AU | 214 AU |
| MK-7 (360 µg/day) | 135 AU | 150 AU | 184 AU |
That works out to a median rise of about 49 AU on MK-7 versus about 69 AU on placebo. The between-group difference was statistically significant (P = .02), including after adjustment for covariates. Calcium mass, a second CT-based measure, showed a similar result.
Calcification still progressed in the MK-7 group. It just progressed more slowly.
Who Was Studied
The researchers randomized 180 patients, 90 per group, at one university hospital and one community hospital in the Netherlands. The analysis covered 85 patients on MK-7 and 82 on placebo.
- Age: median 59 years (MK-7) and 61 years (placebo)
- Sex: 42% female in both groups
- Condition: symptomatic atherosclerotic CAD with moderate calcium (CAC 50-400 AU)
- Baseline balance: the two groups were comparable
This was a relatively young, middle-aged group with established but not extreme calcification. Results may not carry over to people with very high CAC, no symptoms, or kidney disease.
It Wasn't Just Calcium Scores: The Plaque Detail
The most interesting part of the paper is where the effect seemed to come from. Participants also had CT angiography, which lets researchers look at plaque type. The rise in CAC score correlated with the number of noncalcified plaques that became partially calcified during the study (R² = 0.17; P = .04).
The authors' interpretation is that MK-7 may slow calcification in noncalcified plaques. The correlation is modest, since an R² of 0.17 means most of the variation is explained by other factors. It points to a plausible mechanism rather than proving one.
There is also a biological sanity check. Plasma MK-7 rose from a median of 0.50 µg/L to 6.56 µg/L in the treatment group (P < .001), so participants were taking the supplement and absorbing it. That matters because adherence problems can quietly sink supplement trials.
Safety
The authors reported no significant adverse effects. For a two-year trial of a supplement, that is reassuring, though a trial of this size can't rule out rare problems.
What We Don't Know
This is where the headline needs honest limits.
- The clinical meaning is unproven. The authors say the significance of the finding "in terms of plaque stability remains to be determined." Slower calcification is a imaging result, not a reduction in heart attacks, strokes, or death. Calcification is also a complicated marker. Some calcified plaque may be more stable than soft plaque, so slower calcification is not automatically good.
- The absolute difference is modest. About 20 AU separated the groups' median increases over two years.
- The trial was not large. About 167 analyzed patients is enough to detect a CAC difference but not clinical events.
- The timeline was long and interrupted. Data were collected from 2012 through 2022 "with a few interruptions."
- There is an industry link. Prof Leon Schurgers reported receiving grants from Gnosis by Lesaffre, a maker of MK-7, and holding shares in Coagulation Profile, both described as outside the submitted work. That doesn't invalidate the results, but it is worth knowing. An accompanying commentary in the same issue of the journal also weighs in on the findings.
Practical Takeaways
Dose: The trial used 360 µg of MK-7 per day. That is the only dose with this evidence behind it, and it is higher than the amounts in many multivitamins.
Form: MK-7, not MK-4. The study tested menaquinone-7 only. It did not test MK-4 or vitamin K1, so these results shouldn't be assumed to apply to them. It also tested MK-7 against placebo on its own, not as part of a combination formula.
Timing: The abstract doesn't specify when participants took it. Vitamin K is fat-soluble, so taking it with a meal containing some fat is the common-sense approach. That is general guidance, not something this trial tested.
Who it might be relevant for: The evidence applies to people like those enrolled, meaning middle-aged adults with symptomatic CAD and moderate coronary calcification. If that describes you, it's a reasonable topic to raise with your cardiologist. It shouldn't replace statins, blood pressure control, or other proven therapy.
Who should skip it, or ask first:
- Anyone on warfarin or another vitamin K antagonist. Vitamin K directly affects how these drugs work, and supplementing can change your INR. Never start MK-7 without your prescriber's involvement.
- People on other anticoagulants or with a clotting history, who should check with their doctor first.
- Anyone hoping it will "reverse" calcification. The trial showed slower progression, not reduction.
- People without heart disease. This trial doesn't tell us whether MK-7 helps healthy adults.
The Bottom Line
VitaK-CAC is a well-designed, placebo-controlled test of a plausible idea, and it produced a statistically significant slowing of coronary calcification with a good safety record. It is encouraging and mechanistically interesting, especially the signal in noncalcified plaques. But it is a surrogate-marker result from a modest trial, with a conflict-of-interest disclosure worth noting. Until larger studies show fewer cardiac events, MK-7 is a promising add-on to discuss with your doctor, not a heart-disease fix.
Source: Vossen LM, de Leeuw PW, Schurgers LJ, et al. Two Years of Menaquinone-7 Supplementation and Coronary Artery Calcification: A Randomized Clinical Trial. JAMA Cardiology. 2026;11(8):719-726. doi:10.1001/jamacardio.2026.1279. ClinicalTrials.gov: NCT01002157. PubMed.